Cannabidivarin, more commonly known as CBDV, is one of the compounds that has only recently been researched. There is no question that the cannabis ban has hampered previous research. dr. L. Vollner identified CBDV for it as early as 1969.
In 1971, Frans and Merkus wrote about CBDV and tetrahydrocannabivarin (THCV), stating that they were "two more components of hashish." Only recently did CBDV become the subject of detailed research, well over 40 years after its first identification.
CBDV is the result of the chemical reaction of CBGA with selected enzymes. cannabidivarin is also the precursor molecule of CBD, as the cannabinoid has not yet undergone decarboxylation. And, like CBD, will CBDV does not cause a high, making it a viable candidate for medical research.
What is CBDV?
CBDV is one of hundreds of chemicals naturally produced by the cannabis plant known as cannabinoids. Like its chemical counterparts, the CBDV cannabinoid works with your body's endocannabinoid system to create a range of effects. In many ways, CBDV functions similarly to cannabidiol (CBD), particularly in terms of its potential therapeutic properties.
Cannabidivarin (CBDV) is known to harmonize the physiological activity of the cannabis plant. Clinical studies show that cannabidivarin helps with convulsions in humans and animals.
Properties of CBDV
Currently, there are no known adverse side effects associated with the use of CBDV in humans. Possible side effects include those related to the use of CBD, such as dry mouth and low blood pressure.
In short about CBDV:
- Precursor to CBD
- High levels of CBDV have been reported in C. indica strains
- Appears to be effective as a remedy for convulsions (fits)
- Not psychotropic, it does not get you “high”
- Dr. L. Vollner first identified CBDV in 1969
- Affects TRPV1 receptors in the central and peripheral nervous system
Intended medical benefits of CBDV
To date, research suggests that CBDV could be useful in the treatment of seizures, Crohn's disease, symptoms related to HIV / AIDS and multiple sclerosis. CBDV interacts with components of the endocannabinoid system to regulate brain function, and it shows promise in the treatment of epilepsy. Important studies on CBDV include:
- In 2013, researchers concluded that, like THC, CBDV "may have therapeutic potential to reduce nausea." (source)
- A 2018 report concluded that CBDV could be a useful form of treatment for autism spectrum disorder. (source)
- A 2018 article found that CBDV helped improve the health of mice with Rett syndrome, a neurodevelopmental disorder with a range of behavioral and physiological symptoms. (source)
- In 2019, researchers found that CBDV helped improve cognitive, motor and neurological functions related to certain types of genetic disorders. (source)
- Researchers recently published a study suggesting that CBDV may help improve muscle quality and slow muscle degeneration associated with Duchenne muscular dystrophy.
Finally about CBDV
Preliminary research on CBDV shows that this cannabinoid can have a variety of therapeutic effects. The fact that weed has been illegal for quite some time has previously held back further investigation. Keep in mind that researchers first discovered CBDV in 1969. However, few studies have been conducted on its efficacy for treating symptoms of conditions such as epilepsy prior to 2012.
Further research will hopefully show us that CBDV is a potentially useful form of alternative medication.
If this happens, we expect growers to focus on developing CBDV-rich strains, just like CBD. Not many strains currently contain a reasonable level of CBDV; this is expected to change soon.
With the FDA permitting its use, albeit in a very limited sense, the future for CBDV looks bright.